Journal of Thyroid Cancer

Aims and Scope

Journal of Thyroid Cancer (JTC) is a peer-reviewed, open-access platform committed to transforming our understanding of thyroid cancer. We provide an international forum for clinicians, researchers, and healthcare professionals to share groundbreaking research and innovative clinical practices in the diagnosis, treatment, and management of thyroid cancer.
 

Advancing Global Insights in Thyroid Cancer Research and Therapy:

JTC welcomes high-quality submissions that explore a wide spectrum of topics related to thyroid cancer, including:

• Pathological studies detailing tumor characteristics, molecular markers, and genetic alterations.
• Research on the molecular mechanisms, gene expression, and genetic predispositions associated with thyroid cancer.  
• Studies on novel biomarkers and molecular pathways that inform targeted therapies.
• Evaluations of new diagnostic tools and imaging techniques for early detection.  
• Exploration of advanced treatment modalities, including minimally invasive surgical techniques and targeted systemic therapies.
• Contributions that integrate insights from endocrinology, oncology, immunology, and public health to enhance evidence-based practice.

JTC encourage submissions that explore the use of artificial intelligence (AI) algorithms for early detection, risk stratification, and personalized treatment planning in thyroid cancer patients. Contributions from the following research areas are invited but not limited to the following branches 

• Metformin
• Glutathione
• Thyroid Cancer
• Immunotherapy
• Pathophysiology
• Thyroidectomy
• Immune checkpoint inhibitors
• Thyroid carcinoma
• Radioiodine therapy
• Tumor size
• Molecular Biology
• Pathology
• Distant metastasis
• Prognostic factors
• Transcription factors
• Molecular Immunology
• Tumor immune microenvironment
• Resistance to thyroid hormone
• Role of Hormones
• Diagnostic techniques
• Neoplasm metastasis
• Radioactive iodine therapy
• Treatment of medullary thyroid cancer
• Differentiated thyroid cancer (DTC)
• Thyroid-stimulating hormone suppression therapy
• Differentiated thyroid cancers
• Papillary thyroid cancer
• Follicular thyroid cancer
• Medullary thyroid cancer
• Anaplastic thyroid cancer
• Hurthle cell thyroid cancer
• Genetic mutations
• Minimally invasive surgery
• BRAF mutation
• RET mutation
• TERT mutation
• Ionizing radiation
• Lymph node dissection
• Adjuvant therapy
• Chemotherapy
• Targeted therapy
• Hormone therapy
• Recurrent thyroid cancer
• Metastatic thyroid cancer
• Diagnostic tests
• Thyroid ultrasound
• Fine-needle aspiration biopsy
• Thyroid function tests
• Thyroid hormone replacement therapy
• Radioactive iodine scan
• Computed tomography (CT) scan
• Magnetic resonance imaging (MRI)
• Positron emission tomography (PET) scan
• Blood tests
• Molecular testing
• Next-generation sequencing
• Liquid biopsy
• Imaging-guided biopsy
• Endoscopic ultrasound-guided biopsy
• Multimodal treatment
• Surgery followed by radioactive iodine therapy
• Surgery followed by adjuvant therapy
• Adjuvant therapy followed by surgery
• Management of advanced disease
• Molecular targeted therapy
• Tyrosine kinase inhibitors
• Combination therapy